Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
Outline of Final Research Achievements |
We, anesthesiologists have been searching the optimal anesthetic drugs for patients undergoing cancer resection. Such drugs should be expected to keep patients’ natural killer cell cytotoxicity (NKCC) higher after surgery because higher NKCC can contribute to more survival rate due to less metastatic recurrence. Now we conducted this clinical trial to clarify the effect of supplemental ketamine to general anesthesia on the NKCC in patients undergoing prostate cancer resection. In this study patients received general anesthesia with ketamine (ketamine group) or without ketamine (non-ketamine group). The primary outcome was the difference in NKCC between two groups. We found that there was no significant difference in NKCC between two groups, indicating that the addition of ketamine to general anesthesia doesn’t affect NKCC.
|